Potential of cannabinoids as treatments for autism spectrum disorders

V. Nezgovorova, C. J. Ferretti, B. P. Taylor, E. Shanahan, G. Uzunova, K. Hong, O. Devinsky, E. Hollander

Research output: Contribution to journalReview articlepeer-review

Abstract

Current treatments for autism spectrum disorders (ASD) are limited in efficacy and are often associated with substantial side effects. These medications typically ameliorate problem behaviors associated with ASD, but do not target core symptom domains. As a result, there is a significant amount of research underway for development of novel experimental therapeutics. Endocannabinoids are arachidonic acid-derived lipid neuromodulators, which, in combination with their receptors and associated metabolic enzymes, constitute the endocannabinoid (EC) system. Cannabinoid signaling may be involved in the social impairment and repetitive behaviors observed in those with ASD. In this review, we discuss a possible role of the EC system in excitatory-inhibitory (E-I) imbalance and immune dysregulation in ASD. Novel treatments for the core symptom domains of ASD are needed and phytocannabinoids could be useful experimental therapeutics for core symptoms and associated domains.

Original languageEnglish (US)
Pages (from-to)194-201
Number of pages8
JournalJournal of Psychiatric Research
Volume137
DOIs
StatePublished - May 2021

Keywords

  • Autism spectrum disorders
  • Cannabinoids

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Fingerprint

Dive into the research topics of 'Potential of cannabinoids as treatments for autism spectrum disorders'. Together they form a unique fingerprint.

Cite this